Dr Ian Hardcastle
Reader
Natural and Environmental Sciences
New Castle University
United Kingdom
Biography
Dr Ian Hardcastle received his first degree from Bristol University in 1987. He received his PhD in organic synthesis in 1990, from Manchester University, with Dr Peter Quayle. This was followed by a post-doctoral fellowship in the CRC Centre for Cancer Therapeutics at The Institute of Cancer Research with Professor Mike Jarman. Work at the ICR included: studies of the structure activity relationships for tamoxifen analogues, studies into the genotoxic mechanism of tamoxifen. The development of the novel CYP17a inhibitor abiraterone (Zytiga) licenced for the treatment of castrate resistant prostate cancer. The synthesis of novel inhibitors of the Farnesyl Transferase enzyme and the development of novel template-based combinatorial libraries for lead discovery. In November 1999 he joined the Drug Discovery Programme in the Cancer Research Unit now the Newcastle Cancer Centre at the Northern Institute for Cancer Research (NICR), Newcastle University, as a Lecturer in Medicinal Chemistry and is now Reader in Medicinal Chemistry.
Research Interest
Principal Research Interests: medicinal chemistry and drug discovery, targeted anti-cancer agents.
Publications
-
Coxon RC, Wong C, Bayliss R, Boxall K, Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR, Sivaprakasam M, Thomas H, Turner D, Yeoh S, Wang LZ, Griffin RJ, Golding BT, Cano C. Structure-guided design of purine-based probes for selective Nek2 inhibition. Oncotarget 2016, (ePub ahead of Print).
-
Reuillon T, Miller D, Myers S, Molyneux L, Cano C, Hardcastle I, Griffin R, Rigoreau L, Golding B, Noble M. Pyrrolcarboxamide Derivatives for the Inhibition of ERK5. WO/2016/042341, 24/03/2016.
-
Drummond CJ, Esfandiari A, Liu J, Lu X, Hutton C, Jackson J, Bennaceur K, Xu Q, Makimanejavali AR, Bello FD, Piergentili A, Newell DR, Hardcastle IR, Griffin RJ, Lunec J. TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. Oncotarget 2016, 7(29), 46203-46218.
-
Chessari G, Howard S, Buck IM, Cons BD, Johnson CN, Holvey RS, Rees DC, StDenis JD, Tamanini E, Golding BT, Hardcastle IR, Cano CF, Miller DC, Cully S, Noble MEM, Griffin RJ, Osborne JD, Peach J, Lewis A, Hirst KL, Whittaker BP, Watson DW, Mitchell DR. ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY. PCT/GB2016/053042, 06/04/2017.
